

DAFTAR PUSTAKA

- Badan Narkotika Nasional (BNN), 2021, Plant based substances, https://laboratorium.bnn.go.id/?page=daftar_zat_nps diakses pada 29 November 2021.
- Baker, A., Simon, N., Keshaviah, A., Farabaugh, A., Deckersbach, T., Worthington, J. J., Hoge, E., Fava, M., Pollack, M. P., 2019, Anxiety Symptoms Questionnaire (ASQ): development and validation, *General psychiatry*, 32(6).
- Bandelow, B., Michaelis, S., Wedekind, D., 2017, Treatment of anxiety disorders, *Dialogues in clinical neuroscience*, 19(2), 93.
- Chakraborty, S., & Majumdar, S., 2020, Natural products for the treatment of pain: chemistry and pharmacology of salvinorin A, mitragynine, and collybolide, *Biochemistry*, 60(18), 1381-1400.
- Dean, J., & Keshavan, M., 2017, The neurobiology of depression: An integrated view, *Asian journal of psychiatry*, 27, 101-111.
- Dlugos, A. M., Hamidovic, A., Hodgkinson, C., Shen, P. H., Goldman, D., Palmer, A. A., & de Wit, H., 2011, OPRM1 gene variants modulate amphetamine- induced euphoria in humans, *Genes, Brain and Behavior*, 10(2), 199-209.
- Eastlack, S. C., Cornett, E. M., & Kaye, A. D., 2020, Kratom—Pharmacology, clinical implications, and outlook: a comprehensive review. *Pain and therapy*, 9(1), 55-69.
- Fajemiroye, J. O., da Silva, D. M., de Oliveira, D. R., Costa, E. A., 2016, Treatment of anxiety and depression: medicinal plants in retrospect, *Fundamental & clinical pharmacology*, 30(3), 198-215.
- Fluyau, D., & Revadigar, N., 2017, Biochemical benefits, diagnosis, and clinical risks evaluation of kratom, *Frontiers in psychiatry*, 8, p.62.
- Goddard, A. W., 2016, Cortical and subcortical gamma amino acid butyric acid deficits in anxiety and stress disorders: clinical implication, *World journal of psychiatry*, 6(1), 43.
- Grundmann, O., 2017, Patterns of kratom use and health impact in the US—results from an online survey, *Drug and alcohol dependence*, 176, 63-70.
- Hassan, Z., Muzaimi, M., Navaratnam, V., Yusoff, N. H., Suhaimi, F. W., Vadivelu, R., Vicknasingam, B. K., Amato, D., Hörsten, S., Ismail, N. I. W., Jayabalan, N., Hazim, A. I., Mansor, S. M., Müller, C. P., 2013, From Kratom to mitragynine

and its derivatives: physiological and behavioural effects related to use, abuse, and addiction, *Neuroscience & Biobehavioral Reviews*, 37(2), 138-151.

Idayu, N. F., Hidayat, M. T., Moklas, M. A. M., Sharida, F., Raudzah, A. N., Shamima, A. R., Apriyani, E., 2011, Antidepressant-like effect of mitragynine isolated from *Mitragyna speciosa* Korth in mice model of depression, *Phytomedicine*, 18(5), 402-407.

Ismail, I., Wahab, S., Sidi, H., Das, S., Lin, L. J., Razali, R., 2019, Kratom and future treatment for the opioid addiction and chronic pain: periculo beneficium?, *Current drug targets*, 20(2), 166-172.

Kruegel, A. C., & Grundmann, O., 2018, The medicinal chemistry and neuropharmacology of kratom: a preliminary discussion of a promising medicinal plant and analysis of its potential for abuse, *Neuropharmacology*, 134, 108-120.

Kuhn, M., Szklarczyk, D., Pletscher-Frankild, S., Blicher, T. H., Von Mering, C., Jensen, L. J., & Bork, P., 2014, STITCH 4: integration of protein-chemical interactions with user data, *Nucleic acids research*, 42(D1), D401-D407.

Lalanne, L., Nicot, C., Lang, J. P., Bertschy, G., & Salvat, E., 2016, Experience of the use of Ketamine to manage opioid withdrawal in an addicted woman: a case report, *BMC psychiatry*, 16(1), 1-5.

Lin, Y., & Hu, Z., 2021, Bioinformatics analysis of candidate genes involved in ethanol-induced microtia pathogenesis based on a human genome database: GeneCards. *International Journal of Pediatric Otorhinolaryngology*, 142, 110595.

Masih, J., & Verbeke, W., 2019, Exploring association of opioid receptor genes polymorphism with positive and negative moods using Positive and Negative Affective States Scale (PANAS), *Clinical and Experimental Psychology*, 5(1), 1-6.

Meireles, V., Rosado, T., Barroso, M., Soares, S., Gonçalves, J., Luís, Â., Caramelo, D., Simao, A. Y., Fernandez, N., Duarte, A. P., Gallardo, E., 2019, *Mitragyna speciosa*: clinical, toxicological aspects and analysis in biological and non-biological samples, *Medicines*, 6(1), 35.

Moklas, M. A. M., Suliman, N. A., Taib, C. N. M., Hidayat, M. T., Baharuldin, S. F., Zakaria, F. N., Yusof, M. K. M., Adzhar, M. F., Rasul, S. M., Akim, A. M., Amom, Z., 2013, Sedative, cognitive impairment and anxiolytic effects of acute *Mitragyna Speciosa* in rodents. *Differences*, 22(11), 313-17.

Moreno-Rius, J., 2018, The cerebellum in fear and anxiety-related disorders, *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 85, 23-32.

- NIDA, 2019, Kratom DrugFacts, <https://www.drugabuse.gov/publications/drugfacts/kratom> diakses pada 29 November 2021.
- Nisa, R. M., Livana, P. H., Arisdiani, T., 2019, Hubungan dukungan keluarga dengan tingkat ansietas pasien pre operasi major, *Jurnal Keperawatan Jiwa (JKJ): Persatuan Perawat Nasional Indonesia*, 6(2), 116-120.
- Nummenmaa, L., Karjalainen, T., Isojärvi, J., Kantonen, T., Tuisku, J., Kaasinen, V., ... & Rinne, J., 2020, Lowered endogenous mu-opioid receptor availability in subclinical depression and anxiety, *Neuropsychopharmacology*, 45(11), 1953-1959.
- Parikesit, A. A., Dito, A., Riza, A. P., 2017, Pemanfaatan bioinformatika dalam bidang pertanian dan kesehatan, *E-Journal Menara Perkebunan*, 85(2), 105-115.
- Raini, M., 2017, Kratom (*Mitragyna speciosa* Korth): Manfaat, Efek Samping dan Legalitas, *National Institute of Health Research and Development, Indonesian Ministry of Health*.
- Rybarczyk, K. S., 2019, Quantitative Analysis of Mitragynine in Consumer Products Labeled as Kratom, *Doctoral dissertation, University of Illinois at Chicago*.
- Singh, D., Müller, C. P., Vicknasingam, B. K., 2014, Kratom (*Mitragyna speciosa*) dependence, withdrawal symptoms and craving in regular users, *Drug and alcohol dependence*, 139, 132-137.
- Singh, D., Müller, C. P., Murugaiyah, V., Hamid, S. B. S., Vicknasingam, B. K., Avery, B., YeouChear, N. J., Mansor, S. M., 2018, Evaluating the hematological and clinical-chemistry parameters of kratom (*Mitragyna speciosa*) users in Malaysia, *Journal of ethnopharmacology*, 214, 197-206.
- Stelzer, G., Rosen, N., Plaschkes, I., Zimmerman, S., Twik, M., Fishilevich, S., & Lancet, D., 2016, The GeneCards suite: from gene data mining to disease genome sequence analyses. *Current protocols in bioinformatics*, 54(1), 1-30.
- Suhaimi, F. W., Yusoff, N. H., Hassan, R., Mansor, S. M., Navaratnam, V., Müller, C. P., Hassan, Z., 2016, Neurobiology of Kratom and its main alkaloid mitragynine, *Brain research bulletin*, 126, 29-40.
- Suhaimi, F. W., Hassan, Z., Mansor, S. M., Müller, C. P., 2021, The effects of chronic mitragynine (Kratom) exposure on the EEG in rats, *Neuroscience letters*, 745, 135632.
- Surijadi, S., Simadibrata, C., Srilestari, A., Purba, J. S., Purwata, R., 2018, Effect of electroacupuncture therapy on serum serotonin levels of patients with anxiety

- symptoms, *In Journal of Physics: Conference Series* (Vol. 1073, No. 6, p. 062041). IOP Publishing.
- Swogger, M. T., & Walsh, Z., 2018, Kratom use and mental health: a systematic review, *Drug and Alcohol Dependence*, 183, 134-140.
- Swogger, M. T., Hart, E., Erowid, F., Erowid, E., Trabold, N., Yee, K., Parkhust, K. A., Priddy, B. M., Walsh, Z., 2015, Experiences of kratom users: a qualitative analysis, *Journal of psychoactive Drugs*, 47(5), 360-367.
- Szklarczyk, D., Santos, A., Von Mering, C., Jensen, L. J., Bork, P., & Kuhn, M., 2016, STITCH 5: augmenting protein–chemical interaction networks with tissue and affinity data, *Nucleic acids research*, 44(D1), D380-D384.
- Szklarczyk, D., Gable, A. L., Nastou, K. C., Lyon, D., Kirsch, R., Pyysalo, S., Doncheva, N. T., Legeay, M., Fang, T., Bork, P., Jensen, L. J., & von Mering, C., 2020, The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets, *Nucleic acids research*, 49(D1), D605-D612.
- Tanguay, P., 2011, Kratom in Thailand: Decriminalisation and community control? Series on legislative reform of drug policies No. 13, Transnational Institute, *International Drug Policy Consortium (IPDC)*.
- The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2021, Kratom Drug Profile, https://www.emcdda.europa.eu/publications/drug-profiles/kratom_en, diakses pada 10 Desember 2021.
- Vermaire, D. J., Skaer, D., Tippetts, W., 2019, Kratom and general anesthesia: a case report and review of the literature, *A&A Practice*, 12(4), 103-105.
- Wahyono, S., Widowati, L., Handayani, L., Sampurno, O. D., Haryanti, S., Fauzi, F., Ratnawati, G., Budiarti, M., 2019, Kratom: Prospek Kesehatan dan Sosial Ekonomi.
- Wang, J., Duncan, D., Shi, Z., Zhang, B., 2013, WEB-based gene set analysis toolkit (WebGestalt): update 2013. *Nucleic acids research*, 41(W1), W77-W83.
- White, C. Michael, 2018, Pharmacologic and clinical assessment of kratom, *The Bulletin of the American Society of Hospital Pharmacists*, 75(5), 261-267.
- Yusoff, N. H., Suhaimi, F. W., Vadivelu, R. K., Hassan, Z., Rümmler, A., Rotter, A., Amato, D., Dringenberg, H. C., Mansor, S. M., Navaratnam, V., Müller, C. P., 2014, Abuse potential and adverse cognitive effects of mitragynine (kratom), *Addiction biology*, 21(1), 98-110.
- Żmudzka, E., Sałaciak, K., Sapa, J., Pytka, K., 2018, Serotonin receptors in depression and anxiety: Insights from animal studies, *Life sciences*, 210, 106-124.